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In the accompanying paper  (1),  we have shown that  after day 4 of the immune 
response of AKR/J mice to 2,4,6-trinitrophenyl-lys-Ficoll (TNP-F) 1, the addition of 
free hapten to a  plaque-forming-cell (PFC)  assay increased the number of observed 
splenic anti-trinitrophenol  (TNP)  PFC. Immune spleen cells,  taken  7 d  after immu- 
nization, transferred this property of the immune response to normal recipients; spleen 
cells  from  such  recipients,  assayed  4  d  after  cell  transfer  and  TNP-F  injection, 
manifested  an  exaggerated form of this phenomenon. It was hypothesized that  the 
increase in PFC was the result of the displacement, by hapten, of auto-anti-idiotypic 
antibodies that were synthesized during the course of the normal immune response. 
If this  hypothesis  were  correct,  it  should  be  possible  to  obtain  auto-anti-idiotypic 
antibodies by hapten elution  from appropriate immune spleen cells.  Results  in  the 
accompanying paper (1) also suggested that the putative auto-anti-idiotypic-antibody 
response was involved in the downward regulation of the immune response of AKR/ 
J  mice to TNP-F. One might, therefore, expect to find auto-anti-idiotypic antibody 
in the serum of AKR/J mice immediately after the abrupt decrease in the number of 
detectable splenic PFC: i.e.,  7 d after antigen injection. 
In  the  present  paper,  evidence  is  presented  to  support  these  hypotheses  in  that 
hapten-reversible inhibition of PFC in vitro can be demonstrated with hapten eluates 
from immune cells and with immune serum. The factor responsible for inhibition has 
immunoglobulin-like determinants,  lacks anti-TNP-antibody activity, and is absorb- 
able by an AKR/J anti-TNP-antibody immunoadsorbent. Hapten-reversible inhibi- 
tion  of PFC  represents  a  simple  in  vitro  assay  for anti-idiotypic  antibody.  In  this 
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paper, the conditions for such an assay are defined. In addition, we present evidence 
to support the view that the increase in PFC observed in the presence of free hapten 
(1)  represents  an  assay for cells whose  secretion of antibody has  been  inhibited, in 
vivo, by the binding of auto-anti-idiotypic antibodies to cell-surface receptors. The 
data are consistent with the interpretations of others that auto-anti-idiotypic antibod- 
ies are formed during the course of the normal immune response (2-7). 
Materials  and  Methods 
Mice and Immunization.  AKR/J male mice, 6-8 wk of age, were obtained from The Jackson 
Laboratory, Bar Harbor, Maine. AKR/J congenitally athymic, homozygous for the recessive 
gene, nu (nu/nu) mice were obtained by breeding heterozygote ( +/nu) AKR/J mice purchased 
from The Jackson Laboratory. Mice were immunized by the intravenous injection of 10/~g 
TNP-F. Pools of antisera were obtained 7 d after immunization. 
Reagents and Antigens.  Preparation of TNP-F has been described (1). TNP-human  gamma 
globulin  (TNP-HGG)  was  prepared  by  the  reaction  of 2,4,6-trinitrobenzene sulfonic  acid 
(TNBSO~;  Sigma Chemical Co., St. Louis, Mo.) with human  gamma globulin, and dinitro- 
phenylated human serum albumin (DNP-HSA) was prepared by the reaction of 1-fluoro-2,4- 
dinitrobenzene (Eastman Chemical Products, Inc., Eastman Kodak Co., Rochester, N. Y.) with 
human serum albumin (HSA) (8). Conjugated proteins were purified by extensive dialysis and 
their concentrations  were  determined  by  dry-weight  analysis. TNP-c-amino-n-caproic acid 
(TNP-EACA) was prepared by the reaction of TNBSO3 with e-amino-n-caproic acid (9). Mouse 
gamma globulins (MGG) were prepared by two sequential precipitations, at 40% cold saturated 
ammonium  sulfate,  followed by  dialysis against  phosphate-buffered saline  (PBS-D,  Grand 
Island Biological Co., Grand Island, N. Y.). Mouse Fab fragments were kindly provided by Dr. 
A. Nisonoff (Brandeis University, Waltham, Mass.). 
Anti-MGG was prepared by immunization of a goat with 100 ~g MGG, in complete Freund's 
adjuvant  (CFA), injected intramuscularly into four dorsal sites. Rabbit anti-mouse Fab was 
prepared by immunization with 1 mg Fab, in CFA, injected into multiple sites. The antiserum 
gave a single line against Fab fragments and against whole mouse serum in Ouchterlony plates. 
Rabbit anti-TNP antiserum was obtained after immunization with 500 ~g TNP-HGG in CFA. 
Gamma globulin fractions of the rabbit antisera were prepared (10). 
Immunoadsorbents.  An anti-mouse-immunoglobulin immunoadsorbent was prepared as de- 
scribed by Wigzell (11).  Briefly, MGG was adsorbed onto glass beads followed by the addition 
of goat anti-MGG. The columns were washed extensively with PBS-D before use. A  dinitro- 
phenol, DNP-HSA-BAC, (DNP)  immunoadsorbent was prepared by coupling DNP-HSA to 
bromoacetylcellulose (BAC) (12).  For absorption of sera, 1 ml of packed DNP-HSA-BAC was 
used per 0.5 ml of serum. A mouse anti-TNP-antibody immunoadsorbent was prepared by the 
addition of 0.5 ml of primary day-7 anti-TNP-F antiserum, obtained from nu/nu AKR/J mice, 
to a  1-ml DNP-HSA-BAC column.  After 1 h  at  room temperature, the anti-TNP antibody 
immunoadsorbent was washed extensively with PBS-D, and was used for absorption of sera as 
described above for DNP-HSA-BAC. 
Cell Transfers.  Spleen cells from TNP-F-immunized, or nonimmunized, mice were trans- 
ferred, together with antigen, into normal, nonirradiated, syngeneic recipients as described (1). 
Preparation of Eluatefrom Immune Spleen Cells.  4 d after cell transfer and antigen injections (10 
/~g TNP-F), recipients of immune (primary d-7 ant i-TNP-F), or normal, spleen cells were killed. 
Spleen-cell suspensions (5 ×  107/ml), in Hanks' balanced salt solution (Grand Island Biological 
Co.), were incubated, for 30 min at 37°C in the presence of 10  -8 M  TNP-EACA. Supernates 
(eluates)  were  recovered by centrifugation  (1,500  rpm)  at  4°C  for  15  rain,  and  were  then 
dialyzed against PBS-D, at 4°C, overnight. 
In  Vitro Assay for Hapten-Reversible Anti-TNP PFC Inhibitory Factor(s).  Primary day-4 anti- 
TNP-F spleen cells from AKR/J mice were used as target cells in this assay. Cells from ~ooled 
spleens or from individual donors were washed once and were resuspended at 1-2  ×  10  cells/ 
ml.  1-ml aliquots were incubated with various dilutions of cell eluates or with pools of anti- 
TNP-F antisera, for 5 min, at room temperature. The cells were centrifuged  (1,000  rpm,  10 156  AUTO-ANTI-IDIOTYPIC ANTIBODY 
min, room temperature) and, after one wash, were resuspended to the original concentration. 
50 #1 was assayed,  in duplicate, for anti-TNP PFG. The haptenreversibility of the inhibition 
was determined by addition of free hapten (1  X  10  -7-1  X  10  -8 M TNP-EAGA) to the agarose 
and the complement solution.  Further details of the PFG assay have been described (1). 
Results 
In  Vitro Inhibitory Activity of Anti-TNP-F Serum on PFC.  Serum from AKR/J  mice, 
obtained 7 d after the intravenous injection of 10 #g TNP-F, was tested for its ability 
to  inhibit  anti-TNP  plaque  formation  by spleen  cells  from mice immunized  with 
TNP-F 4 d  previously. As indicated in Table I, a  24-99% decrease in the number of 
plaques was observed with  three independent  pools of antisera,  and  three pools of 
immune cells. With a  single pool of cells, the degree of inhibition  varied from 24 to 
43%. Results obtained with pools of spleen cells, and with spleen cells from individual 
donors were comparable. The suppressive effect of the anti-TNP-F antiserum could 
be reversed by hapten in all cases. A single lot of antiserum suppressed (blocked) the 
PFC  from individual  mice to different  extents  (11-56%;  Table I). In addition,  the 
concentration  of  free  hapten  which  caused  maximal  augmentation  of  PFC  was 
different  in  individual  animals  and  ranged  from  1  X  10  -s  to  1  ×  10  -7  M  TNP- 
EACA.  The inhibitory activity was specific for anti-TNP  PFG,  in  that  it  failed  to 
inhibit anti-sheep-erythrocyte (SRBC) PFC (Table II). 
The  kinetics  of PFC  inhibition  at  4°C  and  at  room  temperature  (22°C)  were 
studied  (Table III). At both temperatures, maximum inhibition was observed at the 
shortest incubation period studied  (5 min). With increased incubation periods, there 
was a progressive decrease in inhibition of PFC which was more pronounced at room 
temperature than at 4°C. All further studies were therefore carried out with a  5-rain 
incubation period. 
The  nature  of the  interaction  leading  to  inhibition  of antibody  secretion  was 
studied. Neither rabbit anti-TNP-HGG antibody nor rabbit anti-mouse Fab inhibited 
anti-TNP  PFC  (Table IV). Addition  of TNP-F to the  immune spleen  cells clearly 
decreased  their  capacity  to  produce  anti-TNP  plaques.  It  should  be  emphasized, 
however, that this in vitro inhibition, by polyvalent antigen, was not hapten reversible 
under the conditions of the present assay and, therefore, differed fundamentally from 
the effect of immune serum (Table IV). 
Characterization of the PFC Inhibitory Activity  in  Anti-TNP-F Antiserum.  To  test  the 
hypothesis that the hapten-reversible PFC inhibitory activity present in the immune 
sera was due to anti-idiotypic antibodies, the inhibitory factor was characterized by 
absorption studies.  Passage of the antiserum through a  DNP-HSA-BAC immunoad- 
sorbent did not alter its inhibitory activity (Table V). It was shown by a solid-phase 
radioimmunoassay (13),  that  after passage through  this  immunoadsorbent  column, 
the serum  contained  <10  ng/ml  anti-TNP  antibody.  Thus,  the  inhibitory  activity 
was present in spite of the absence of anti-TNP antibody and, furthermore, remained 
reversible by addition of hapten to the PFC assay. Passage of the antiserum through 
an anti-MGG column (11) eliminated PFC inhibitory activity (Table V). Based upon 
these  absorption  studies,  it  was  concluded  that  the  inhibitor  was  a  molecule  with 
immunoglobulin-like determinants but was not anti-TNP antibody. 
Finally,  the  serum  was  passed  through  an  anti-TNP-F.DNP-HSA-BAC  column 
(that is, an anti-TNP-antibody immunoadsorbent). This adsorbent was prepared by E.  GOIDL,  F.  SCHRATER, G.  SISKIND, AND J.  THORBECKE  157 
TABL~  I 
Inhibition of Anti- TNP-F PFC by Antiserum  from Mice Immunized with TNP-F 7 d Previously and 
Reversal of the Inhibition by Addition of Hapten* 
Percentage of control response after incubation with 
Control re-  PFC  NMS  Pool I  Pool II  Pool III 
source:~  sponse  (direct 
PFC/spleen)  Hapten  Hapten  Hapten  Hapten  Hapten  Hapten  Hapten  Hapten 
absent  present§  absent  present  absent  present  absent  present 
Pooled 
spleens 
1  82,000  100  99  1  105  .... 
2  19,000  100  126  63  147  76  179  57  131 
3  164,000  100  101  ....  59  102 
Individual 
spleens 
1  164,000  100  102  82  102  75  98 
2  100,000  100  102  68  106  74  100 
3  202,000  100  99  67  101  73  107 
4  182,000  100  101  64  98  61  99 
5  99,000  100  101  44  113  63  101 
6  37,000  100  103  89  103  --  -- 
7  22,000  100  105  109  100  --  -- 
m 
m 
m 
m 
m 
* Immune cells  (1-2  X  10S/ml) were incubated  with immune serum or normal  mouse serum  (NMS), 
usually at a  1:20 final dilution, for 5 min at room temperature.  NMS was obtained from a pool of 20 
mice. Pools of immune serum were obtained from groups of 5-20 AKR/J mice immunized with 10 pg 
TNP-F, intravenously, 7 d before bleeding. 
:~ Spleens from 2-5 AKR/J mice immunized 4 d earlier with  10 #g TNP-F, intravenously, were pooled. 
Individual mice were immunized similarly. 
§ Maximum number of PFC/spleen observed in the presence of 10-s-10  -7 M TNP-EACA. 
addition,  to DNP-HSA-BAC,  of day-7  immune  antiserum  from nu/nu  AKR/J  mice 
immunized  with  10/tg TNP-F  intravenously.  It had been shown, z that  nu/nu  AKR/ 
J  mice did not produce the PFC inhibitory factor in spite of their high anti-TNP  PFC 
response  to the T-independent  antigen,  TNP-F.  These  mice, therefore,  were a  likely 
source of idiotype-bearing anti-TNP  antibody  that was not contaminated  with auto- 
anti-idiotypic antibody. The anti-TNP-antibody  column removed all detectable PFC 
inhibitory  activity  (Table  V).  Because  the  DNP-HSA-BAC  column  itself failed  to 
remove the PFC  inhibitory  activity, it was  concluded  that  the inhibitory  factor had 
been bound  to the anti-TNP  antibodies.  It should be noted that  a  similarly prepared 
anti-dansyl-antibody  column  (anti-dansyl.dansyl-HSA-BAC)  failed  to  remove  the 
anti-TNP  PFC  inhibitory  activity from  the  serum  of TNP-F  immunized  mice. The 
results were thus  consistent  with the interpretation  that  the inhibitor was  an immu- 
noglobulin-like molecule with anti-idiotype specificity (anti-anti-TNP). 
E-lution and Characterization of the PFC Inhibitory Activity from Immune Spleen Cells.  Based 
upon  the  hypothesis  that  hapten  augmentation  of plaque  formation  was  due  to 
displacement  of bound  auto-anti-idiotypic  antibodies,  it  would  be predicted  that  a 
a Schrater et al. Manuscript in preparation. 158  AUTO-ANTI-IDIOTYPIC ANTIBODY 
TABLE II 
Inhibition of Anti-TNP-F PFG by Antiserum fiom Mice Immunized with 
TNP-F 7 d Previously: Specificity of Inhibitory Activity* 
Experiment  Antiserum~ 
Direct PFC/slide§ 
Anti-TNP  Anti-SRBC 
Hapten  Hapten  Hapten  Hapten 
absent  present  absent  present 
1  NMS  164  166  178  184 
Pool IV  96  166  175  180 
NMS  135  133  220  ND u 
Pool VI  102  135  225  ND 
Pool VII  79  125  225  ND 
Anti-SRBC  133  135  230  ND 
* Immune spleen cells were obtained from groups of five AKR/J mice that had been 
immunized, intravenously, with  10/~g TNP-F or with 4  ×  10  s SRBC 4  d  before 
assay. 
Pools of immune sera were obtained from grousps of 5-20 AKR/J  mice that  had 
been immunized with  10 #g TNP-F or 4  x  10  SRBC, intravenously, 7 d  before 
bleeding. All cell suspensions were pretreated with the antisera for 5 min at 4°C, 
were washed once, and were resuspended and plated. 
§ PFC were assayed, after pretreatment, so that  1/100 (anti-SRBC) or 1/1,000 (anti- 
TNP) of a spleen equivalent was plated per slide. 
]] ND, not done. 
factor  inhibitory  for  PFC  could  be  eluted  from  appropriate  immune-spleen-cell 
populations,  i.e.,  from  recipients  of  immune  spleen  cells  plus  antigen.  A  large 
proportion of anti-TNP PFC  in such recipients are blocked, but can be revealed in 
vitro by hapten  (1).  As indicated  in Table VI, a  hapten eluate prepared from such 
cells markedly inhibited anti-TNP plaque formation. The inhibition could be reversed 
by the inclusion of 10  -s M  TNP-EACA in the assay mixture. Inhibition was specific, 
in that  the material had no effect on anti-SRBC  PFC.  A  similarly prepared eluate 
from recipients of immune cells from nu/nu  AKR/J  mice did not inhibit  anti-TNP 
PFC (data not shown). 
Results  in  Table VI also indicate  that  the  eluted  factor was similar to the  PFC 
inhibitor  in  serum.  It  was not  anti-TNP  antibody because  it  was  not  removed by 
DNP-HSA-BAC, and it was immunoglobulin-like because it was removed by an anti° 
MGG immunoadsorbent. After passage through either column, the eluate lacked anti- 
TNP-antibody activity. Like the serum inhibitor, the factor in the eluate was removed 
by passage through  the  anti-TNP-antibody column.  These results strongly support 
the previous conclusion that this factor is an anti-idiotypic antibody that is produced 
during the normal course of the immune response to TNP-F. 
Discussion 
In  the  accompanying paper  (1),  we  demonstrated  an  in  vitro  augmentation  by 
hapten  of the  number  of PFC  detected  in  recipients  4  d  after transfer of TNP-F 
immune spleen cells and antigen. It was proposed that this was due to the displacement 
of auto-anti-idiotypic antibodies from antibody-producing cells. In the present paper E.  GOIDL, F.  SCHRATER, G.  SISKIND, AND J.  THORBECKE 
TABLE III 
Effect of Varying Incubation Conditions on the Inhibition of Anti-TNP PFC by 
Serum from Mice Immune to TNP-F 
Incubation conditions  Percentage of control response after 
incubation with* 
159 
Time  Temperature  Antiserum:]:  NMS 
mm  °C  % 
5  4  57§  100 
15  4  76  102 
30  4  72  102 
5  22  66  101 
15  22  78  99 
30  22  86  106 
* Control  response  (164,000 anti-TNP  PFC/spleen)  was  determined after 
incubation of day-4 immune spleen cells (1-2  ×  106/ml) with NMS (1:20) 
for 5 min at 4°C. PFC were assayed, after pretreatment, such that  1/1,000 
of a spleen equivalent was plated per slide. 
Day-4 immune spleen cells (1-2 ×  10n/ml) were incubated with a 1:20 final 
dilution of a  pool of immune  serum  taken  from  AKR/J mice  7 d  after 
intravenous injection of 10 #g TNP-F. All the data in the table are derived 
from PFC determinations in the absence of hapten in the assay. 
§ In the presence of 10  -a M TNP-EACA, PFC returned to 101% of control. 
we  have  demonstrated  the  existence  of  a  factor  in  the  serum  of  AKR/J  mice, 
immunized with  TNP-F  7  d  earlier, that  inhibits, in vitro, anti-TNP  PFC, but  not 
anti-SRBC  PFC. The inhibitory factor was specific for anti-TNP PFC, was antigen- 
ically immunoglobulin-like, but was not anti-TNP antibody. Inhibition of PFC was 
reversible by TNP-hapten. A  factor with similar characteristics was eluted, by hapten, 
from spleen cells of AKR/J  mice that had a  high proportion of hapten-augmentable 
PFC. The factor present in the eluate as well as in the serum was removed by passage 
over an anti-TNP antibody column but not by a  TNP-HSA-BAC column. Thus, the 
results are consistent with  the view  that  the  PFC  inhibitory factor is an  auto-anti- 
idiotypic antibody that is specific for the idiotypes of some of the AKR/J  anti-TNP 
antibodies. Because the eluates were prepared by incubation with hapten, at 37°C, it 
is possible that the factor in the eluates was, at least in part, actively secreted during 
the incubation rather than simply dissociated from the cell surface. However, it seems 
unlikely that significant amounts of inhibitor could be secreted during the relatively 
short (30 min)  incubation period. 
It  has  been  proposed by Jerne  (14)  that  the  immune  response  is regulated by a 
network of idiotype-anti-idiotype interactions. The  data presented here offer direct 
support for the in vivo operation of such an idiotype-specific regulatory network. It is 
interesting  to  recall  the  classic  observation  that  the  increase  in  immunoglobulin 
concentration  during  immunization  is  often  too  great  to  account  for  in  terms  of 
antibody specific for the immunizing antigen  (15-17).  Some of this immunoglobulin 
may be auto-anti-idiotypic antibodies. 
Several lines of evidence support  the conclusion that  the PFC  inhibitory factor is 
not  anti-TNP  antibody:  (a)  inhibitory activity is not  removed by absorption with a 
TNP  immunoadsorbent;  (b)  rabbit anti-TNP  antibody fails to inhibit TNP-specific 
plaque  formation,  and  (c)  anti-TNP-F  antiserum  from  nude  mice does  not  inhibit 160  AUTO-ANTI-IDIOTYPIC ANTIBODY 
TABLE IV 
Lack of Specific Hapten-Reversible In  Vitro Inhibition of Day-4 Anti-TNP PFC by 
Various Antisera and Antigens 
Pretreatment of immune 
Experiment  spleen cells* 
Direct anti-TNP PFC/slide~ 
Hapten absent  Hapten present 
NMS  101  106 
Rabbit anti-TNP-HGG  106  102 
Rabbit anti-mouse Fab  112  120 
AKR/J anti-TNP-F (Pool III)  55  103 
TNP-F (1.0/~g/ml)  54  54 
TNP-F (0.1/Lg/ml)  52  53 
NMS  135  133 
AKR/J anti-TNP-F (Pool VI)  102  135 
TNP-F (1.0 #g/ml)  38  50 
TNP-F (0.001/tg/ml)  43  42 
* Immune spleen cells were obtained from groups of five AKR/J mice that had been 
immunized with 10/tg TNP-F intravenously 4 d before assay. The cells (1-2 ×  106/ 
ml) were pretreated for 5 min ~t 4°C with  the antigens  and antisera indicated. 
Gamma globulin  fractions of rabbit anti-TNP-HGG and rabbit anti-mouse  Fab 
were used at a final concentration of 12.5 #g protein/ml. The anti-TNP hemagglu- 
tination titer at this dilution was 1:500. Anti-TNP-F antiserum was obtained from 
a pool of AKR/J mice 7 d after intravenous injection of 10/~g TNP-F. 
:]: After pretreatment the cells were washed once and were resuspended for PFC assay 
so that 1/1,000 of a spleen equivalent was plated per slide. 
anti-TNP  plaque  formation,  a  This  latter  point  deserves  special  emphasis  because 
TNP-F  is  a  T-independent  antigen  and  elicits an  excellent response  in  nude  mice 
(18). Thus, anti-TNP antibody is probably not responsible for the PFC inhibition. It 
is  to  be  expected  that  the  anti-idiotypic-antibody response  to  anti-TNP  antibody 
would be T-dependent as are responses to most protein antigens. 
It thus appears that  anti-idiotypic antibody can  reversibly inhibit secretion by B 
cells.  Inhibition  of plaque  formation  by  anti-idiotypic antibody  has  been  seen  by 
several previous workers (19, 20). The mechanism of this inhibition is not known, but 
there is precedence for reversible inhibition of antibody secretion by the cross-linking 
of cell-surface antigen receptors. Effector-cell blockade (21,  22), in which polyvalent 
antigens inhibit antibody secretion, appears to represent such a  situation. Inhibition 
of secretion is induced rapidly and is reversible if the antigen is removed from the cell 
surface by treatment with appropriate enzymes. It is of interest that although TNP-F 
did inhibit plaque  formation,  the inhibition was  not  hapten  reversible, and  thus  is 
operationally distinct from the inhibition by anti-idiotypic antibody. The difference 
in ease of hapten  reversibility might lie in the extent of cross-linking involved in the 
two phenomena. It is probable that with the highly polyvalent antigen, TNP-F, more 
bonds  to cell-surface antigen  receptors are formed  than  with  the  bi- or oligovalent 
anti-idiotypic antibodies.  Increasing the  number  of bonds  formed would  markedly 
decrease the ease with which displacement by hapten would occur. Antigen-antibody 
complexes  might  also  inhibit  plaque  formation  (23).  Thus,  it  was  important  to 
a Schrater et al. Manuscript  in preparation. E.  GOIDL,  F.  SCHRATER,  G.  SISKIND,  AND J.  THORBECKE 
TABLE  V 
Characterization of the PFC Inhibitory Activity of Anti-TNP-F Antiserum 
161 
Experiment  Serum source*  Absorption of 
serum:~ 
Percentage of NMS-incubated con- 
trol§ 
Pool  Mouse 1  Mouse 2  Mouse 3 
1  None  Not absorbed  109 
NMS (1:10)  Not absorbed  100 
Anti-TNP-F (1:100)  Not absorbed  36 
Anti-TNP-F (1:200)  Not absorbed  -- 
Anti-TNP-F (1:300)  Not absorbed  -- 
Anti-TNP-F (1 : 10)  DNP-HSA-BAC  39 
Anti-TNP-F (1 : 100)  DNP-HSA-BAC  54 
Anti-TNP-F (1:200)  DNP-HSA-BAC  83 
Anti-TNP-F (1:300)  DNP-HSA-BAC  105 
Anti-TNP-F (1:10)  Anti-MGG  100 
2  NMS (1:10)  Not absorbed  100 
Anti-TNP-F (1:10)  Not absorbed  11 
Anti-TNP-F (1 : 100)  Not absorbed  31 
Anti-TNP-F (1 : 10)  Anti-TNP  98 
Anti-TNP-F (1 : 100)  Anti-TNP  100 
3  NMS (1:10)  Not absorbed  100 
Anti-TNP°F (1 : 10)  Not absorbed  39 
Anti-TNP-F (1:100)  Not absorbed  64 
Anti-TNP-F (1:10)  Anti-dansyl  26 
Anti-TNP-F (1 : 100)  Anti-dansyl  47 
% 
--  68  88 
100  100  100 
30  41  50 
64  78  83 
84  76  83 
25  37  30 
60  59  50 
64  67  68 
84  102  80 
84  100  87 
m 
* NMS was a  pool from 20 AKR/J mice. A  pool of immune serum was taken from 20 mice 7 d  after 
intravenous immunization with 10 #g TNP-F. 
:~ DNP-HSA-BAC and anti-MGG immunoadsorbent columns were prepared as described in Materials and 
Methods. Anti-TNP antibody columns were prepared by incubation of primary (10 #g TNP-F intrave- 
nously) day-7 anti-TNP-F serum from AKR/J nu/nu mice, with DNP-HSA-BAC, at room temperature, 
for  1 h, followed by extensive washing with PBS-D. An anti-dansyl antibody immunoadsorbent (anti- 
dansyl.dansyl-HSA-BAC)  was  prepared  and  used  in  a  manner  similar  to  the  anti-DNP-antibody 
immunoadsorbent. 
§ Pooled immune spleen cells from five AKR/J mice, immunized intravenously 4  d  earlier with  10 #g 
TNP-F, were incubated at 1-2  ×  106 cells/ml with the various serum preparations, for 5 min, at room 
temperature. The cells were washed once, and were then assayed for anti-TNP PFC. The 100% values for 
PFC determined in the presence of NMS were: experiment 1: Pool,  76,000 PFC/spleen; mouse 1, 88,000 
PFC/spleen;  mouse 2, 63,000  PFC/spleen;  mouse 3, 60,000  PFC/spleen; experiment 2:  Pool,  154,000 
PFC/spleen; experiment 3: Pool,  170,000 PFC/spleen. In the presence of 10-s-10  -7 M TNP-EACA, all 
PFC values returned to 100% of the NMS control determined in the absence of hapten. 
establish,  as  was  done  in  the  present  studies,  that  the  inhibitory  activity  was  not 
removed  by absorption  with antigen. Furthermore,  the presence of immune  complexes 
in  antigen  excess  was  considered  unlikely  in  that  the serum  contained  a  high  anti- 
TNP-antibody  titer. 
The  observations reported  here suggest  that  hapten-reversible  inhibition of plaque 
formation  by  immune  serum  represents  a  convenient  assay  for  auto-anti-idiotypic 
antibodies.  The  approach  to  assaying  anti-idiotypic  antibodies  described  here  is 
equally  applicable  to  the  detection  of  the  spontaneous  production  of  auto-anti- 
idiotypic  antibody.  The  short  incubation  period  used  in  the  assay  is  essential,  as 162  AUTO-ANTI-IDIOTYPIC ANTIBODY 
TABLE VI 
Characterization of the PFC Inhibitory Activity Eluted by Hapten from Immune Spleen Cells* 
Inhibitor absorbed  Percentage of NMS 
lnhibitor:~  Source  Dilution 
with§  controlll 
% 
NMS  Nonimmune AKR/J  mice  1:10  Not absorbed  100 
Anti-TNP-F serum  Day-7 primary immune AKR/J  mice  1:10  Not absorbed  4 
Anti-TNP-F serum  Day-7 primary immune AKR/J  mice  1:100  Not absorbed  33 
Anti-TNP-F serum  Day-7 primary immune AKR/J  mice  1:200  Not absorbed  90 
Spleen-cell eluate  Normal-cell transfer recipients  1:10  Not absorbed  85 
Spleen-cell el uate  Immune-cell transfer recipients  l:10  Not absorbed  27 
Spleen-cell eluate  Immune-cell transfer recipients  I: 10  DNP-HSA-BAC  34 
Spleen-cell eluate  Immune-cell transfer recipients  I: 10  Anti-MGG  89 
Spleen-cell eluate  Immune-cell transfer recipients  1:10  Anti-TNP-F  100 
* Immune spleen cells from AKR/J  mice (pool of five)  immunized 4 d earlier with  10/xg TNP-F, intravenously, were incubated at  I-2  ×  10  n 
cells/ml with the various inhibitors for 5 rain at room temperature.  The cells were washed once and were then assayed for anti-TNP-PFC. 
:[¢ NMS was obtained  from a  pool of 20 AKR/J  mice. Pools of immune serum were obtained  from groups of 5-20 AKR/J  mice immunized, 
intravenously, with  10/tg TNP-F 7 d  before bleeding. Spleen cell eluates were prepared  in the following manner: 4 d after intravenous cell 
transfer and antigen injection (10 ~tg TNP-F), recipients of immune (primary day-7 anti-TNP-F)  or normal spleen cells were killed. Spleen- 
cell suspensions (5  ×  10  v cells/ml) were incubated for 30 min at 37°C in the presence of 1 ×  10  s M  TNP-EACA. Supernates (eluates) were 
recovered by centrifugation  (1,500 rpm) at 4°C for  15 min followed by overnight dialysis against PBS-D at 4°C. 
§ The anti-TNP-F (anti-TNP. DNP-HSA-BAC)  immunoadsorbent column was prepared by incubation of primary day-7 anti-TNP-F (10/tg 
intravenously) serum from AKR/J  mice, with DNP-HSA-BAC at room temperature  for one h, followed by extensive washing with PBS-D. 
II In the presence of 10  -8  10  7 M  TNP-EACA, all PFC values returned to  100% of the NMS control determined in the absence of hapten. 
prolonged  incubation,  especially  at  room  temperature,  yielded  less  inhibition  of 
plaque  formation.  Presumably,  this  progressive  loss  of inhibition  upon  prolonged 
incubation reflects the capping and disappearance from the surface of idiotype-anti- 
idiotype complexes. 
Pools  of anti-idiotypic-antibody-containing antisera  inhibited  anti-TNP  plaque 
formation to varying degrees when tested on d-4 PFC  from individual mice of the 
same strain. This suggests that the assay may detect variability in idiotype expression. 
Variation in the representation of major idiotypes in sera from individual mice of the 
same strain has been noted by previous workers (24, 25). 
It  should  be emphasized  that  two  distinctly different interactions are occurring 
simultaneously in  this assay:  (a)  hapten  "displacement" of anti-idiotypic antibody, 
due  to  the  binding of hapten  to  the  cell-surface antigen  receptors, leading  to  the 
visualization of additional  antibody-secreting cells;  (b)  hapten  inhibition of plaque 
formation at the target cell level, as a result of the binding of hapten to the secreted 
antibody; thereby blocking the interaction of the latter with the hapten-conjugated 
SRBC.  The observed change in  the number of PFC  is consequently the combined 
effects of these two factors that act in opposite directions. Therefore, the number of 
hapten-augmentable PFC detected represents a  minimal estimate of the number of 
anti-idiotype-blocked antibody-synthesizing cells.  One must also consider the impli- 
cations of the phenomenon reported here on the use of hapten inhibition of PFC as 
an assay of antibody affinity. Clearly the existence of hapten-augmentable PFC will 
bias the results of affinity measurements by decreasing the number of high-affinity 
PFC detected as well as reduce the observed heterogeneity. Provided this bias is born 
in mind, hapten-inhibition data can still provide a useful estimate of PFC affinity. It 
is necessary to perform studies over a wide range of hapten concentrations to detect 
any augmentation of the number of PFC. The precise shape of the curve describing 
the effect of increasing hapten concentration on the number of PFC will be determined 
by the combination of the two factors noted above, and will  be influenced by the E. GOIDL, F.  SCHRATER, G. SISKIND, AND J. THORBECIKE  163 
affinity of the anti-idiotypic antibody for the idiotype, and the affinity of the antibody 
(idiotope) for the hapten. 
The ease with which low concentrations of hapten reverse the inhibition and bring 
about the displacement of anti-idiotypic antibody suggests that such inhibition may 
operate reversibly in vivo. That is,  a  steady-state condition may prevail in vivo in 
which inhibition by auto-anti-idiotypic antibodies, and activation as a consequence 
of their dissociation, might occur continuously. The number of PFC normally detected 
(or the serum-antibody level achieved) would reflect the operation of such a homeo- 
static mechanism. The present work thus supports the view that auto-anti-idiotypic 
antibody may be spontaneously induced during an  immune  response to a  foreign 
antigen  (1)  and suggests that  its formation is involved in the normal regulation of 
immune reactivity. 
Summary 
Sera taken from AKR/J mice 7 d  after the intravenous injection of 2,4,6-trinitro- 
phenyl-lys-Ficoll (TNP-F)  caused a  specific inhibition of anti-trinitrophenol  (TNP) 
plaque-forming cells (PFC) in vitro. This inhibition was reversed by the incorporation 
of 10-s-10  -7  M  2,4,6-trinitrophenyl-E-amino-n-caproic acid  (TNP-EACA)  into  the 
agar  during  the  PFC  assay.  The  factor responsible  for the  hapten-reversible  PFC 
inhibition  was  removed from  serum  by  passage  through  an  anti-immunoglobulin 
column or through a 2,4,-dinitrophenyl-human-serum-albumin-bromoacetylcellulose 
plus anti-TNP-antibody column, but not by DNP-HSA-BAC alone. It was concluded 
that this immunoglobulin-like substance, lacking anti-TNP activity but reacting with 
anti-TNP antibody of AKR/J origin, was most likely an auto-anti-idiotypie antibody 
that had been produced during the normal course of the response of AKR/J mice to 
TNP-F.  Pools  of  anti-idiotypic-antibody-containing  antisera  inhibited  anti-TNP 
plaque formation to varying degrees when tested on d-4 PFC from different mice of 
the same inbred strain, suggesting a variability in idiotype expression. 
4 d  after transfer of immune (7 d after 10 #g TNP-F, administered intravenously) 
AKR/J  spleen  cells  plus  10 #g TNP-F  into  syngeneic mice,  the  number  of PFC 
detectable in the recipients' spleens could be markedly augmented by the inclusion of 
TNP-EACA in the agar during the PFC assay. Incubation of spleen cells containing 
such hapten-augmentable  PFC with TNP-EACA yielded a  factor in the supernate 
that caused a specific, in vitro, hapten-reversible inhibition of anti-TNP PFC. Studies 
with immunoadsorbents indicated that this PFC-inhibiting factor was antigenically 
immunoglobulin-like, lacked anti-TNP-antibody activity, but reacted with anti-TNP 
antibody of AKR/J  origin. The results are consistent with  the view that  this  PFC 
inhibitor is auto-anti-idiotypic antibody that is involved in the normal regulation of 
the immune response. 
It  is  proposed that  hapten-reversible inhibition of plaque  formation can be em- 
ployed as an assay for anti-idiotypic antibody and the conditions for such an assay 
are described. It is further proposed that the detection of hapten-augmentable PFC 
suggests the presence of auto-anti-idiotypic antibody. 
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